NA-Semax Amidate
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
NA-Semax Amidate is a chemically modified form of Semax, a synthetic peptide originally derived from a fragment (positions 4–10) of the hormone ACTH. The “N-acetyl” and “amidate” modifications refer to changes at the two ends of the peptide chain that are intended to protect it from the enzymes that normally break Semax down quickly in the body.
Because of these modifications, it is commonly described as having greater stability and bioavailability than standard Semax. It is studied in the nootropic category, where interest centers on cognitive performance, focus, and neuroprotection.
Most of the underlying research is on the parent compound, Semax, and much of it comes from animal models or from studies conducted in Russia, where Semax is used clinically. Human clinical data on the acetylated amidate form specifically is limited.
How it works
In preclinical studies, Semax has been reported to increase the expression of brain-derived neurotrophic factor (BDNF) and its receptor (trkB) in the hippocampus — a brain region central to learning and memory. BDNF is a signaling protein associated with the growth, survival, and plasticity of neurons, which is the basis for the compound’s proposed cognitive effects.
Researchers have also studied Semax’s activation of neurotrophin gene transcription following cerebral ischemia, and its effects in animal models of neurodegeneration. The acetyl and amidate modifications in NA-Semax Amidate are thought to help more of the intact peptide reach these pathways, though the precise mechanism and its relevance in humans are not firmly established.
Reported benefits
- Enhanced focus, mental clarity, and working memory (largely reported, limited human data)
- Support for neuroplasticity via BDNF and related neurotrophic pathways (animal data)
- Neuroprotective effects studied in models of stroke and neurodegeneration (preclinical)
- Mood and stress resilience effects described anecdotally
These are reported or studied effects, not guaranteed outcomes, and much of the evidence is preclinical.
Considerations & side effects
Because rigorous human trials on NA-Semax Amidate are lacking, its long-term safety profile is not well characterized. Reported side effects are generally mild and, with intranasal use, can include nasal irritation, mild headache, or fatigue. Some users describe changes in alertness or sleep.
Product purity varies widely in the research-chemical market, and formulations sold under the same name may differ. It is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is NA-Semax Amidate?
A modified version of Semax, a synthetic peptide derived from the ACTH(4-10) fragment. The N-terminal acetylation and C-terminal amidation are intended to slow enzymatic breakdown, giving it greater stability and bioavailability than standard Semax. It is studied primarily for cognitive and neuroprotective effects.
Is NA-Semax Amidate FDA-approved?
No. It is not approved by the FDA or any major Western regulator for human therapeutic use and is sold for research purposes only. The parent compound, Semax, is a registered medicine in Russia but has not been through the same approval process elsewhere.
How does it differ from regular Semax?
The acetyl and amidate modifications are designed to resist the enzymes that quickly degrade unmodified Semax. This is commonly reported to extend its duration and improve how much reaches the brain, though head-to-head human comparisons are limited.
How is it typically administered?
In the research setting it is most often given intranasally, the same route used for Semax in published studies.
Is the evidence based on human trials?
Most mechanistic evidence comes from animal models of Semax. Human data specific to the acetylated amidate form is very limited, and much of what is claimed is extrapolated from the parent peptide.
References
- Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. ↗
- Dmitrieva VG, et al. Semax and Pro-Gly-Pro Activate the Transcription of Neurotrophins and Their Receptor Genes after Cerebral Ischemia. ↗
- Radchenko AI, et al. The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease. ↗
Related compounds
Synthetic analog of ACTH (4-10) with nootropic and neuroprotective properties. Enhances BDNF expression and supports cognitive performance and focus.
A synthetic adamantane derivative (actoprotector) marketed in Russia as Ladasten for asthenia and fatigue. It has mild dopaminergic, anti-fatigue, and stimulant-like actions without the rebound of classic stimulants. A small molecule, not a peptide.
Standardized neuropeptide preparation with neurotrophic and neuroprotective properties. Used clinically in 50+ countries for stroke recovery, traumatic brain injury, and dementia treatment.